LEADING REGENERATIVE MEDICINE

Annual Meeting

Tuesday, Oct. 22, 2013

Palm Springs, CA

2

Cautionary Statement Concerning Forward-Looking Statements

This presentation is intended to present a summary of ACT’s (“ACT”, or “Advanced

Cell Technology Inc”, or “the Company”) salient business characteristics.

The information herein contains “forward-looking statements” as defined under the

federal securities laws. Actual results could vary materially. Factors that could cause

actual results to vary materially are described in our filings with the Securities and

Exchange Commission.

You should pay particular attention to the “risk factors” contained in documents we

file from time to time with the Securities and Exchange Commission. The risks identified

therein, as well as others not identified by the Company, could cause the Company’s

actual results to differ materially from those expressed in any forward-looking

statements. Ropes Gray

CEO UPDATE

Gary Rabin Chief Executive Officer, Chairman

3

4

• We continue to appreciate your support through this period where we

are working to finally put the past to rest. We share your frustration with

how long it has taken to put the last matters to closure

• We concluded highly successful meeting with our OAB

• We have worked through a 2014 goal-driven plan with our senior

management team to advance both our clinical RPE program and our

other ophthalmic activities, as well as moving our MSC activities

toward the clinic

• We are at the beginnings of seeing a real opportunity in our pre-

clinical animal studies and translating that into a veterinary plan

• We are starting to engage fully in our up-listing and institutional capital

raising strategy, and are optimistic that we will finally achieve our

goals.

ACT Overview

5

Pre-clinical/ in vitro

POC – Animal Studies IND Approved Phase I Phase II Phase III Approval

Dry AMD

SMD

MMD

Photo-receptors

Ganglion

Neurons

Cornea

Platelets

Mesenchymal Stem Cells

Robust Development Pipeline Provides Multiple Opportunities to

Commercialize and Partner O

ph

tha

lmo

log

y P

rog

ram

s

6

Pre-clinical/ in vitro

POC – Animal Studies IND Approved Phase I Phase II Phase III Approval

Dry AMD

SMD

MMD

Photo-receptors

Ganglion

Neurons

Cornea

Platelets

Mesenchymal Stem Cells

Robust Development Pipeline Provides Multiple Opportunities to

Commercialize and Partner

Potential Gov’t Funding

First Priority Based On Current Funding

Advance into Phase I and Partner

Based on POC results,

pursue appropriate

funding and collaborations

Op

hth

alm

olo

gy

Pro

gra

ms

Several Important clinical milestones Q4 2013, 2014

150K 200K ?

Cohort 2a

100K

1Q 2014 Jan 2015

Dry AMD

& SMD Trials

Patient follow-up

PII design Patient Treatment Phase II

Patient Treatment MMD Trial

7

4Q 2013 3Q 2014

Phase I

Phase I

8

BY PRODUCING THE

HIGHEST DEGREE OF QUALITY

VETERINARY THERAPEUTICS

WE INTEND TO BE

A LEADER IN

VETERINARY

REGENERATIVE MEDICINE

September 19, 2013 –

“ACT Files Investigational New Animal

Drug (INAD) Application with FDA to Treat

10 Different Disease Indications Using

Pluripotent Stem Cells”

9

• Extremely successful and productive meeting

• Complete unanimity among company, investigators, and

independent board members

• Plan agreed on Phase 2 trial design including endpoints and

termination strategy for current trials

• Currently developing materials to discuss strategy with FDA

• Data review and results showing surprising strong statistical success.

All board members impressed by aggregate data showing acuity

improvements as well as differential between treated and untreated

eyes

• Working on beginning to write paper for submission to top peer

reviewed medical journals

Ophthalmic Advisory Group Summary

SCIENCE UPDATE

Dr. Robert Lanza Chief Scientific Officer

10

Treatment of eye diseases

• Retinal pigment epithelium (macular degeneration)

• Retinal ganglion progenitors (glaucoma)

• Photoreceptor progenitors (advanced blindness)

• Mesenchymal stem cells (uveitis)

• Corneal endothelium (corneal repair)

Single-blastomere technology

• Master Cell Bank (ethically-compliant/xeno-free) for future clinical trials

Induced pluripotent stem (iPS) cell technology

• Episomal, mRNA, microRNA vs. other reprogramming methods

• Master Cell Bank for Phase I/II clinical trials

Megakaryocytes/platelets

• Preclinical studies safety & efficacy studies

Mesenchymal stem cells

• Manufacturing under GMP conditions (for pre-clinical/clinical studies)

• Rodent studies (multiple sclerosis, lupus, pain, ALS, Alzheimer's)

• Large-animal studies (hepatitis, glomerulonephritis, osteoarthritis, Crohn’s disease, IBS,

spinal cord/disc disease, meningoencephalitis, hemolytic anemia, pancreatitis, sepsis)

Research & Development Programs

11

Ocular Programs

Retinal pigment epithelium

Macular degeneration (AMD, Stargardt’s)

Myopia

Retinal ganglion progenitors

Glaucoma

Retinal neural progenitors

Photoreceptor replacement

Neuroprotection

Corneal endothelium

Corneal disease

Mesenchymal stem cells

Uveitis, glaucoma

light

Retina

12

RPE Clinical Trials

US Clinical Trials

• Jules Stein Eye Institute (UCLA)

• Wills Eye Institute

• Bascom Palmer Eye Institute

• Mass Eye & Ear

Dry AMD

Twelve patients treated

- 3 patients (50K cells)

- 6 patients (100K cells)

(includes 3 better vision)

- 3 patients (150K cells)

Stargardt’s Disease

Nine patients treated

- 3 patients (50K cells)

- 4 patients (100K cells)

(includes 1 better vision)

- 2 patients (150K cells)

July 12, 2011: First patient in both US trials were treated

at UCLA by Steven Schwartz, M.D.

Stargardt’s Disease

Nine patients treated

- 3 patients (50K cells)

- 3 patients (100K cells)

- 3 patients (150K cells)

European Clinical Trial Site

• Moorfields Eye Hospital

ClinicalTrials.gov US: NCT01345006, NCT01344993 UK: NCTO1469832

13

OVERALL RESULTS:

No major safety issues related to stem cell treatment

Clear signs of long-term engraftment & survival

During the one-year follow-up period, patients in both the

SMD and dry-AMD clinical trials have shown significant

improvement in visual acuity in the RPE-treated eyes

• vision in one patient improved from

20/400 to 20/40 in first month

By contrast, the fellow (untreated) eyes remained

unchanged or continued to show decline in visual acuity

during the same time period

DAY 1 2 MONTHS 6 MONTHS

14

Next Steps – RPE Program

Complete and publish results of Phase I/II Clinical Trials

Preparation and design of Phase II Clinical Trials

NED-7 GMP Master Cell Bank (MCB) – hESCs derived using single-blastomere technology (no embryos destroyed)

– No mouse feeders (no longer a xeno product)

– MCB (~500 vials generated) » Working Cell Bank (~260 vials generated)

» ~800 vials of RPE (made from 2 vials of WCB)

(enough to treat ~800 patients, although could have generated more)

* waiting for manufacturing and regulatory sign-offs

Begin Phase I Clinical Trial (UCLA) to treat myopia

15

Megakaryocytes & Platelets

• hES/iPSC-platelets participate in clot formation

• Incorporate into mouse thrombus

(laser-induced arteriolar injury)

Both hES and iPS-MKs produce pure platelets

Normal blood platelets iPS-derived platelets

16

Glycogen

Granules Dense Tubular

System

Open

Canalicular

System

Alpha-Granule Mitochondria

Micro-

tubules

Multivesicular

Body

Glycogen

Granules

Alpha-Granule

Mitochondria

Open

Canalicular

System

Dense Tubular

System Microtubules

Morphology/ultrastructure of iPS-platelets

identical to normal blood platelets

iPS-PLT

blood-PLT

17

Achieve

1 Million Dose Scale

1yr 2yr 3yr 4yr 5yr 10yr

NEXT STEPS / PLATELET PROGRAM

Optimize MK progenitor/platelet production &

functionality in vitro

Scale-up using microfluidics and bioreactor system

Continue preclinical testing in animals (efficacy,

biodistribution, safety/tox tumorigenicity)

Complete transfer of technology to

GMP/manufacturing (includes assay development and

process validation)

Complete clinical regulatory process/file IND

NOTE: Strategic decision made to fast-track MSC program into clinic

first (potentially greater financial and medical impact in the near term )

18

Corneal repair: corneal endothelium derived from hESCs

• 10 million people with corneal blindness

• Cornea the most transplanted organ (1/3 due to endothelial failure)

• Solutions: Tx of whole cornea “Penetrating Keratoplasty” (PKP)

– More popular: Tx corneal endothelium & Descemet’s membrane (DSEK)

Global gene analysis shows that hESC-

CECs & adult-CECs are nearly identical

Optimized

cryopreservation

(CECs can now be

sent world-wide)

19

hESC-derived cells resemble normal human corneal endothelium

Next Steps

Preclinical Studies

Continue testing hESC-derived corneal endothelium

in in vivo rabbit cornea model

• Model: In vivo edema injection in rabbit

(inject dissociated cells to replace native

CECs)

• Increase purity of CECs to 99%

• Design and test hydrogel sheet in vitro (needs

to be transparent, flexible and biodegradable)

• Design and test CEC/hydrogel sheet in vivo

(test sheet to mimic clinical DSEK in rabbit

model)

Cornea Iris

Lens

CEC

20

Other Retinal Cell Types

Pluripotent

Stem Cell

Eye Field

Stem Cell

RNP

Photoreceptor

Ganglion

PDE6a/DAPI

Opsin (green/red)

PDE6a/DAPI

Rhodopsin/Recoverin

Math5/DAPI

21

Retinal Neural Progenitors

a-wave (cones & rods)

b-wave (post-synaptic retinal cells)

RNP, 2 mo RNP, 2 mo

RNP, 1 mo

PBS, 1 mo

PBS, 2 mo

RNP, 1 mo

PBS, 1 mo

PBS, 2 mo

Increase in retinal (ONL)

thickness by OCT after 2 mos

hESC- RNP cells reversed the progression of

photoreceptor degeneration

0

20

40

60

Control No Injection Cell treatment Th

ick

nes

s of

ON

L (

µm

)

} ONL ONL }

22

Identification of endocrine/neuroprotective factors

mouse specific probe

human specific probe

Genomic DNA Q-PCR analysis

of whole retina

Proteins screened using antibody arrays

23

Preservation of Outer Segments (OS) of Rod Photoreceptors in RCS rats

PBS

Tail vein injection

Intravitreal injection

Missing OS

Rod OS in cell-treated

rat retina shown by

rhodopsin staining

24

Subretinal transplantation Integration of Photoreceptor PROGENITORS

1 week after transplantation 3 week after transplantation

HNA antibody/transplanted human cells Human cells migrating into ONL

25

Next Steps Continue testing RNPs in in vitro and in animal models

Collaborations underway with several leading groups studying various retinal/ocular disease

models

Continue identification of paracrine/neuroprotective factors (proteomics, antibody arrays, 2D

gel analysis, and mass spec)

Test ability of cell-free lysates (or specific identified factors) to prevent or delay a range of

ocular & non-ocular degenerative diseases

Photoreceptor Progenitors

Complete studies of recovery of host visual function and retinal structure

Continue in vitro neuroprotection studies using conditioned medium

In vitro and in vivo functional tests of secreted factors

Ganglion Progenitors

Continue animal experiments/show long term survival of transplanted cell

Integration of transplanted cells

Protection/replacement of host retinal ganglion cells

Optic nerve regeneration

26

Mesenchymal Stem Cells (MSCs)

Found in bone marrow, adipose, umbilical

cord, tooth buds

Can differentiate into fat, bone, cartilage

MSCs are immunoprivileged and can:

- migrate to injury site

- exert immunosuppressive effects

- facilitate tissue repair

Over 200 clinical trials

(www.clinicaltrials.gov)

- wide range of clinical indications being

pursued

- companies such as Pluristem,

Mesoblast, Neostem are developing

MSC-based therapies using BM or

other primary sources of MSCs

27

hESC-MSCs versus adult derived MSCs

● “Off the shelf” therapy available for immediate use

● Unlimited cell source

● Easy to derive

● Can be expanded to large numbers in vitro

● More youthful and live much longer

● Potentially greater efficacy

(older MSCs often serve as negative controls)

● Hemangioblast-derived hESC-MSCs exponentially

greater yields than other reported hESC methods

>30,000 X more units from hESC-MSCs

than from adult bone marrow MSCs

A sampling of their in vivo efficacy

will be given in the following slides

28

Treatment of Multiple Sclerosis in Mice (EAE model)

Clinical Score: 2-4

(partial to complete

hind/front leg paralysis)

Untreated hESC-MSC Treated* Clinical Score: <1

(no leg paralysis)

*BM-MSCs had minimal impact (animals still showed paralysis)

hESC-MSCs dramatically reduce clinical

symptoms of EAE

both prophylactic and therapeutic

inhibition

In vitro inhibition of T-cell function

Differential cytokine expression (hESC-

MSCs vs. BM-MSCs)

Differential ability to migrate into damaged

tissues (hESC-MSCs vs.

BM-MSCs)

Additional follow-up studies being

completed for scientific publication (based

on reviewer suggestions)

Multiple sclerosis is a leading candidate for

clinical translation

29

hESC-MSC treatment for Uveitis

An inflammatory/auto-immune condition of the uvea

Accounts for 10% of blindness in US (mostly 20-40

year olds)

Experimental autoimmune uveitis (EAU) in mice

resembles

that of human uveitis

Disease state can be assessed using funduscope

imaging/histology

PMN and lymphocytes

Untreated EAU mice

Preliminary studies show

that hESC-MSC treatment

is effective in treating EAU

uveitis

30

hESC-MSC treatment for SLE/Lupus Nephritis Systemic lupus erythematosus (SLE) or lupus is a systemic autoimmune disease that can

effect virtually any organ or system in the body

There is no cure for SLE

SLE most often harms the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous

system

50% of SLE patients get lupus nephritis (LN)

Immune complex deposition in kidney glomeruli leads to kidney dysfunction/failure

NZB/NZW mice spontaneously develop lupus nephritis (very similar to human SLE)

NZB/NZW lupus model

hESC-MSCs have a dramatic effect on

morbidity (including proteinuria/kidney

function

Protect from death (show marked

improvement in survival)

Lead candidate for clinical translation

31

hESC-MSC treatment for Pain

PAIN behavior can be

measured in mice using

operant equipment (using a

reward/conflict paradigm)

hESC-MSCs significantly

reduce chemotherapy-

induced neuropathy in

response to taxol

Also a candidate for clinical

translation

32

Potential therapeutic applications for MSCs

>100 autoimmune diseases

Multiple Sclerosis

Osteoarthritis

Lupus

Aplastic Anemia

Crohn’s Disease/IBS

Chronic Pain

Limb Ischemia

Heart Failure/MI

Stroke

Graft-versus-host Disease

Spinal Cord Injury

Liver Disease

Kidney Disease

Emphysema/Pulmonary Diseases

Wound healing (ulcers/decubitus/burns)

HSC engraftment/irradiated cancer patients

Eye diseases (uveitis, retinal degeneration, glaucoma)

hES/hiPS-MSCs are

Ideal for Clinical Translation

No need for immunosuppression

Persist transiently

Can be irradiated

33

Canine Indications for Human MSC Therapy

MSC Therapy

Orthopedic

Intervertebral disk disease

Osteoarthritis

Inflammatory

Sepsis

Acute pancreatitis

Immune-mediated

Granulomatous meningoencephalitis

Inflammatory bowel disease

Chronic hepatitis

Glomerulonephritis

Anal furunculosis

Immune-mediated hemolytic anemia

Filed Investigational New Animal Drug (INAD)

application with the FDA to treat 10 different

disease indications

Naturally-occurring diseases in large animals,

such as dogs, provide an excellent model of

human conditions. May provide a more robust

assessment of safety and therapeutic endpoints

than what can be obtained from inbred rodent

models

Initiated collaboration with Tufts University

School of Veterinary Medicine, which has a large

population of suitable patients, and world-experts

in regenerative medicine

Have already received IACUC approval to begin

several of the studies

In additional to the obvious veterinary

applications, the results may help inform and

optimize human clinical trials

34

CORPORATE UPDATE

Ted Myles Chief Financial Officer & EVP of Corporate Development

35

Improving the Balance Sheet, and therefore the Company to Position a 2014 up-listing

36

ACT - Current

~$4m - $5m cash on hand and funding

itself through bi-daily issuances of

~2.5m shares of common stock

The Company draws from the market

slightly less than it spends, in order to

build its cash balance, albeit slowly

This funding vehicle puts continuous

downward pressure on stock and is not

enabling of scale up as we prepare for

larger clinical trials

ACT – end of 2013/early 2014

Raising a tranche of funds ($10m - $15m) in

the near-term will improve the balance

sheet, and therefore the stability of the

company

Will also decrease our reliance on the

frequent draws, therefore reducing the

constant downward pressure on the stock

Having ~12 months of cash in the bank will

allow the Company to be more strategic as

it pursues clinical expansion, corporate

development and Nasdaq listing

ACT has never had real balance sheet strength and has therefore

been forced to make decisions from a “less than optimal” position

Why Up-List to Nasdaq?

37

“Over-the-Counter”

OTC companies are sometimes

associated as being of “poor quality”

Naked shorting can damage

shareholder value

Trading/liquidity is less efficient

Equity research analysts want to cover

and support companies on national

exchanges

Institutional investors who can invest

substantial capital are less likely to

invest in “penny stocks” no matter how

great the company

Nasdaq Listed

“Class effect”, being a Nasdaq-listed

company carries with it a cache of quality,

based partly on perception and largely on the

strict listing requirements

Increased shareholder protection due to

stringent listing requirements

Institutional investors have expressed

interest in investing substantial capital into

ACT, after up-listing

Building a syndicate of equity research

analysts who cover the Company can create

additional demand for the shares

Completing a fully marketed financing deal that includes a broad syndicate of

bankers and analysts could capitalize the Company through Phase II, and create

global awareness of the ACT story

Management

believes that

a Nasdaq up-

listing is in

the best

interest of all

stakeholders

Clinical and Corporate Development Support Up-listing,

and Growth in Shareholder Value

38

All components

of the

Company

complement

one another. A

transformative

process for

ACT

R&D

Progress

Phase 1 Phase 2 AMD Trials

MMD Trial Phase 1

Corporate

Development

MSC and

other Pre-clinical

SEC, etc. Clean up

Partnering Non-dilutive

funding

Reverse split Financial Nasdaq “re-IPO”

Thank you

For more information, visit www.advancedcell.com